Dilip Kumar Chanchal
Dilip Kumar Chanchal has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Kuldeep Singh
Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
5 shared publications - Jitendra Singh Chaudhary
Department of Pharmacy, Smt. Vidyawati College of Pharmacy, Jhansi, Uttar Pradesh, India
4 shared publications - Shivendra Kumar
Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
4 shared publications - Nidhi Mittal
Department of Pharmacy, Smt. Vidyawati College of Pharmacy, Jhansi, Uttar Pradesh, India
3 shared publications - Bharat Bhushan
Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
2 shared publications - Divya Jain
Department of Microbiology, School of Applied and Life Sciences, Uttaranchal University, Dehradun-248007, Uttarakhand, India
2 shared publications
Latest Publications
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2) , 1-14
Transforming RNA-Based Gene Therapy with Innovative Nanocarriers for siRNA and miRNA Delivery
The cells have been given precise instructions proprio to the regulation of gene expression by the main genesis of Ryan-based gene therapy, which has revived cancer treatment and other disorders. The difficulty of delivering small interfering RNA (siRNA) and microRNA (miRNA) to a target cell is an enormous task and is often faced by researchers due to characteristic instabilities of these carriers and their poor uptake by the cell membrane. The new developments from nanocarrier technologies offer opportunities for better effectiveness of RNA therapy for its delivery and the effectiveness of the treatment regimen. The objective of this article is to provide an overview of the existing as well as the newest developments in nanocarrier technology, particularly as related to microRNA and small interfering RNA (siRNA) delivery. Their modes of operation and their uses in gene therapies are also examined as principles of their design. We focus on several nanocarrier technologies, which have shown proof of concept in multiple disciplines such as stability, controlled release profiles, and delivery. Lipid-based nanoparticles, polymeric systems, and hybrid nanocarriers are some of the platforms that fall under this category; however, this list is not exhaustive. We also study the idea that certain nanocarriers could have multiple functionalities, which would make it possible to improve cancer treatment by simultaneously carrying chemotherapy and genes. We aim to shed light on the future of RNA-based gene therapy by providing a thorough overview of recent research in the field. This will help us understand how novel nanocarrier technologies can tackle the delivery issues.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2) , 1-14
Transforming RNA-Based Gene Therapy with Innovative Nanocarriers for siRNA and miRNA Delivery
The cells have been given precise instructions proprio to the regulation of gene expression by the main genesis of Ryan-based gene therapy, which has revived cancer treatment and other disorders. The difficulty of delivering small interfering RNA (siRNA) and microRNA (miRNA) to a target cell is an enormous task and is often faced by researchers due to characteristic instabilities of these carriers and their poor uptake by the cell membrane. The new developments from nanocarrier technologies offer opportunities for better effectiveness of RNA therapy for its delivery and the effectiveness of the treatment regimen. The objective of this article is to provide an overview of the existing as well as the newest developments in nanocarrier technology, particularly as related to microRNA and small interfering RNA (siRNA) delivery. Their modes of operation and their uses in gene therapies are also examined as principles of their design. We focus on several nanocarrier technologies, which have shown proof of concept in multiple disciplines such as stability, controlled release profiles, and delivery. Lipid-based nanoparticles, polymeric systems, and hybrid nanocarriers are some of the platforms that fall under this category; however, this list is not exhaustive. We also study the idea that certain nanocarriers could have multiple functionalities, which would make it possible to improve cancer treatment by simultaneously carrying chemotherapy and genes. We aim to shed light on the future of RNA-based gene therapy by providing a thorough overview of recent research in the field. This will help us understand how novel nanocarrier technologies can tackle the delivery issues.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25 (4) , 374-393
Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy
The immune system presents significant obstacles to gene therapy, which has limited its use in treating many illnesses. New approaches are needed to overcome these problems and improve the effectiveness of gene therapy. This study explores several techniques to immune regulation within gene therapy, a cutting-edge discipline that aims to optimise results by fine-tuning the immune response. We cover new ways to control the immune system and deliver therapeutic genes just where they are needed, including influencing immunological checkpoints, causing immunotolerance, and making smart use of immunomodulatory drugs. In addition, the study provides insight into new developments in the design of less immunogenic gene delivery vectors, which allow for the extension of transgene expression with minimal adverse immune reactions. In order to maximise the efficacy of gene-based therapies, this review analyses these novel approaches and gives a thorough overview of the present state of the art by addressing obstacles and pointing the way toward future developments in immune regulation. Not only does their integration provide new opportunities for the creation of safer and more effective gene treatments, but it also contains the key to overcome current obstacles.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25 (4) , 374-393
Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy
The immune system presents significant obstacles to gene therapy, which has limited its use in treating many illnesses. New approaches are needed to overcome these problems and improve the effectiveness of gene therapy. This study explores several techniques to immune regulation within gene therapy, a cutting-edge discipline that aims to optimise results by fine-tuning the immune response. We cover new ways to control the immune system and deliver therapeutic genes just where they are needed, including influencing immunological checkpoints, causing immunotolerance, and making smart use of immunomodulatory drugs. In addition, the study provides insight into new developments in the design of less immunogenic gene delivery vectors, which allow for the extension of transgene expression with minimal adverse immune reactions. In order to maximise the efficacy of gene-based therapies, this review analyses these novel approaches and gives a thorough overview of the present state of the art by addressing obstacles and pointing the way toward future developments in immune regulation. Not only does their integration provide new opportunities for the creation of safer and more effective gene treatments, but it also contains the key to overcome current obstacles.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 689-698
Exploring the Synergistic Antimicrobial Potential of Garlic and Honey: A Comprehensive Review
Aims: This article explores the well-established therapeutic attributes of honey and garlic, renowned for their potent antibacterial effects. This investigation aims to elucidate the synergistic antibacterial potential resulting from the combined use of these two natural substances. Methods: A comprehensive examination of honey's antibacterial and antifungal characteristics is conducted, delineating its intricate mechanism of action with a focus on hydrogen peroxide and other phytochemicals. Simultaneously, various processes underpinning the antibacterial properties of garlic are discussed, with particular emphasis on its key bioactive component, allicin. Results: This research unveils a novel perspective on the interaction between honey and garlic. It is intricately analyzed how garlic's bioactive components disrupt microbial cell membranes, while honey employs diverse tactics to combat illnesses. This interaction opens new possibilities for modern antibacterial approaches. Discussion: Quantitative findings and the significance of the study are discussed in detail. The practical applications of the synergistic antibacterial potential are underscored, emphasizing its relevance in food preservation and medicinal contexts. The research accentuates the promising use of garlic and honey blends as natural alternatives to artificial preservatives, with implications for wound care and infection prevention. Conclusion: Emphasizing the valuable applications of synergistic antibacterial potential across diverse industries, including food preservation and medicine, this study underscores the importance of harnessing the combined antibacterial qualities of garlic and honey as a sustainable solution to emerging challenges in food safety and health.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 689-698
Exploring the Synergistic Antimicrobial Potential of Garlic and Honey: A Comprehensive Review
Aims: This article explores the well-established therapeutic attributes of honey and garlic, renowned for their potent antibacterial effects. This investigation aims to elucidate the synergistic antibacterial potential resulting from the combined use of these two natural substances. Methods: A comprehensive examination of honey's antibacterial and antifungal characteristics is conducted, delineating its intricate mechanism of action with a focus on hydrogen peroxide and other phytochemicals. Simultaneously, various processes underpinning the antibacterial properties of garlic are discussed, with particular emphasis on its key bioactive component, allicin. Results: This research unveils a novel perspective on the interaction between honey and garlic. It is intricately analyzed how garlic's bioactive components disrupt microbial cell membranes, while honey employs diverse tactics to combat illnesses. This interaction opens new possibilities for modern antibacterial approaches. Discussion: Quantitative findings and the significance of the study are discussed in detail. The practical applications of the synergistic antibacterial potential are underscored, emphasizing its relevance in food preservation and medicinal contexts. The research accentuates the promising use of garlic and honey blends as natural alternatives to artificial preservatives, with implications for wound care and infection prevention. Conclusion: Emphasizing the valuable applications of synergistic antibacterial potential across diverse industries, including food preservation and medicine, this study underscores the importance of harnessing the combined antibacterial qualities of garlic and honey as a sustainable solution to emerging challenges in food safety and health.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 634-647
Strategies to Enhance Ocular Penetration of Drugs in Controlled Release Formulations
Objective:: The purpose of this study is to provide a thorough examination of methods for improving ocular medication penetration within controlled-release formulations, with an emphasis on their relevance to the treatment of eye disorders. Method:: Employing a methodical and rigorous methodology, this study provides an in-depth survey of current knowledge and research on the topic. Research on iontophoresis, prodrugs, pH modulation, penetration enhancers, hydrogels, inserts, nanomicelles, microemulsions, dendrimers, contact lenses, cationic emulsions, and targeted drug delivery are only some of the many topics covered in this study. Results:: Results summarise and synthesize prior research to give useful insights into the efficacy and potential of controlled-release formulations in increasing ocular medication delivery, providing a thorough review of current insights into these techniques. Discussion:: The discussion portion of the review critically assesses the guiding principles, advantages, and downsides of each technique, and it also investigates the consequences and prospects for this developing subject. Conclusion:: The study highlights the revolutionary potential of controlled-release formulations in the treatment of ocular illnesses, highlighting the importance of overcoming the obstacles associated with restricted pharmaceutical penetration into ocular tissues. This study concludes the present level of knowledge and paves the way for future improvements in the area of ocular medication administration, making it an essential resource for scientists and medical professionals working on the subject.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 634-647
Strategies to Enhance Ocular Penetration of Drugs in Controlled Release Formulations
Objective:: The purpose of this study is to provide a thorough examination of methods for improving ocular medication penetration within controlled-release formulations, with an emphasis on their relevance to the treatment of eye disorders. Method:: Employing a methodical and rigorous methodology, this study provides an in-depth survey of current knowledge and research on the topic. Research on iontophoresis, prodrugs, pH modulation, penetration enhancers, hydrogels, inserts, nanomicelles, microemulsions, dendrimers, contact lenses, cationic emulsions, and targeted drug delivery are only some of the many topics covered in this study. Results:: Results summarise and synthesize prior research to give useful insights into the efficacy and potential of controlled-release formulations in increasing ocular medication delivery, providing a thorough review of current insights into these techniques. Discussion:: The discussion portion of the review critically assesses the guiding principles, advantages, and downsides of each technique, and it also investigates the consequences and prospects for this developing subject. Conclusion:: The study highlights the revolutionary potential of controlled-release formulations in the treatment of ocular illnesses, highlighting the importance of overcoming the obstacles associated with restricted pharmaceutical penetration into ocular tissues. This study concludes the present level of knowledge and paves the way for future improvements in the area of ocular medication administration, making it an essential resource for scientists and medical professionals working on the subject.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (3) , 267-279
Nanostructures and Niosomes: A Quantum Leap in Clotrimazole Therapeutics
This in-depth analysis examines the revolutionary potential of nanostructures, particularly niosomes, in boosting Clotrimazole's therapeutic effectiveness for dermatological applications. A common antifungal drug called clotrimazole suffers significant problems with solubility, bioavailability, and penetration. Niosomal gels in particular, which are nanostructured drug carriers, have emerged as ground-breaking approaches to overcome these constraints. The study opens with an explanation of the mechanisms of action of Clotrimazole and its wide range of therapeutic uses in dermatology, emphasising the limitations of standard formulations. We present and explore niosomes, lipid-based nanocarriers with diverse characteristics. They provide a viable substrate for improved Clotrimazole administration due to their biocompatibility, adjustable lipid composition, and capacity to encapsulate both hydrophilic and hydrophobic medications. The creation and development of clotrimazole- loaded niosomal gels are at the core of the review. Numerous preparation processes are investigated, and elements affecting the formation of niosomal gel, such as lipid content and optimization strategies, are reviewed. Particle size analysis and encapsulation efficiency testing are two methods for characterising these gels that are covered in depth. The effectiveness of Clotrimazoleloaded niosomal gels is validated in large part by in vitro and in vivo tests. The review explores in vitro drug release investigations, studies of skin permeability and penetration, and comparisons with conventional formulations. When accessible, preclinical and clinical trial insights provide crucial clinical context. The benefits of clotrimazole-loaded niosomal gels, such as greater patient compliance and improved drug delivery, are also covered in the article. It solves difficulties including stability issues and regulatory issues. The review's conclusion emphasises the essential role that nanostructures and niosomes have played in developing Clotrimazole medicines for dermatological usage. It provides a thorough review of current developments, exciting new approaches, and the wider effects of this ground-breaking medication delivery strategy.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (3) , 267-279
Nanostructures and Niosomes: A Quantum Leap in Clotrimazole Therapeutics
This in-depth analysis examines the revolutionary potential of nanostructures, particularly niosomes, in boosting Clotrimazole's therapeutic effectiveness for dermatological applications. A common antifungal drug called clotrimazole suffers significant problems with solubility, bioavailability, and penetration. Niosomal gels in particular, which are nanostructured drug carriers, have emerged as ground-breaking approaches to overcome these constraints. The study opens with an explanation of the mechanisms of action of Clotrimazole and its wide range of therapeutic uses in dermatology, emphasising the limitations of standard formulations. We present and explore niosomes, lipid-based nanocarriers with diverse characteristics. They provide a viable substrate for improved Clotrimazole administration due to their biocompatibility, adjustable lipid composition, and capacity to encapsulate both hydrophilic and hydrophobic medications. The creation and development of clotrimazole- loaded niosomal gels are at the core of the review. Numerous preparation processes are investigated, and elements affecting the formation of niosomal gel, such as lipid content and optimization strategies, are reviewed. Particle size analysis and encapsulation efficiency testing are two methods for characterising these gels that are covered in depth. The effectiveness of Clotrimazoleloaded niosomal gels is validated in large part by in vitro and in vivo tests. The review explores in vitro drug release investigations, studies of skin permeability and penetration, and comparisons with conventional formulations. When accessible, preclinical and clinical trial insights provide crucial clinical context. The benefits of clotrimazole-loaded niosomal gels, such as greater patient compliance and improved drug delivery, are also covered in the article. It solves difficulties including stability issues and regulatory issues. The review's conclusion emphasises the essential role that nanostructures and niosomes have played in developing Clotrimazole medicines for dermatological usage. It provides a thorough review of current developments, exciting new approaches, and the wider effects of this ground-breaking medication delivery strategy.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (1) , 33-44
Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond
: Epigenetic changes are important for controlling how genes are expressed and how cells work, and their misregulation has been linked to many diseases, including cancer. Targeting epigenetic modifiers has become a promising way to treat cancer, and it may also be useful outside of oncology. This review article goes into detail about the rapidly changing field of epigenetic-based therapies, with a focus on how they are used to treat cancer. We discuss in-depth the main epigenetic changes seen in cancer, such as DNA methylation, changes to histones, and dysregulation of noncoding RNA, as well as their roles in tumour growth, metastasis, and drug resistance. Epigenetic drugs and small molecule inhibitors that target epigenetic enzymes and reader proteins have shown a lot of promise in both preclinical and clinical studies on different types of cancer. We show the most recent evidence that these epigenetic therapies work and look into how they might be used in combination with other treatments. We talk about new research into the therapeutic potential of epigenetic modifiers in diseases other than cancer, such as neurological disorders, autoimmune diseases, and heart conditions. Even though there is a lot of potential for therapy, there are still problems, such as side effects and differences between patients. We talk about the work that is still being done to get around these problems and explain new ways to deliver epigenetic-based interventions that are more precise and effective. For epigenetic-based therapies to be used in clinical settings, it is important to understand how they work and how they interact with other types of treatment. As the field moves forward, we try to figure out where it is going and what it means to target epigenetic modifiers in cancer therapy and other areas of disease. This review looks at the role of epigenetic modulation in shaping the landscape of precision medicine and its possible effects on human health from a broad and forward-looking point of view.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (1) , 33-44
Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond
: Epigenetic changes are important for controlling how genes are expressed and how cells work, and their misregulation has been linked to many diseases, including cancer. Targeting epigenetic modifiers has become a promising way to treat cancer, and it may also be useful outside of oncology. This review article goes into detail about the rapidly changing field of epigenetic-based therapies, with a focus on how they are used to treat cancer. We discuss in-depth the main epigenetic changes seen in cancer, such as DNA methylation, changes to histones, and dysregulation of noncoding RNA, as well as their roles in tumour growth, metastasis, and drug resistance. Epigenetic drugs and small molecule inhibitors that target epigenetic enzymes and reader proteins have shown a lot of promise in both preclinical and clinical studies on different types of cancer. We show the most recent evidence that these epigenetic therapies work and look into how they might be used in combination with other treatments. We talk about new research into the therapeutic potential of epigenetic modifiers in diseases other than cancer, such as neurological disorders, autoimmune diseases, and heart conditions. Even though there is a lot of potential for therapy, there are still problems, such as side effects and differences between patients. We talk about the work that is still being done to get around these problems and explain new ways to deliver epigenetic-based interventions that are more precise and effective. For epigenetic-based therapies to be used in clinical settings, it is important to understand how they work and how they interact with other types of treatment. As the field moves forward, we try to figure out where it is going and what it means to target epigenetic modifiers in cancer therapy and other areas of disease. This review looks at the role of epigenetic modulation in shaping the landscape of precision medicine and its possible effects on human health from a broad and forward-looking point of view.
- Top Cited Papers
- 2 December 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (5) , 4673-4687
Natural products as drug leads: exploring their potential in drug discovery and development
Natural products have been pivotal in drug discovery, offering a wealth of bioactive compounds that significantly contribute to therapeutic developments. Despite the rise of synthetic chemistry, natural products continue to play a crucial role due to their unique chemical structures and diverse biological activities. This study reviews and evaluates the potential of natural products in drug discovery and development, emphasizing the integration of traditional knowledge with modern drug discovery methodologies and addressing the associated challenges. A comprehensive literature search was conducted across PubMed/MedLine, Scopus, Web of Science, Google Scholar, and Cochrane Library, covering publications from 2000 to 2023. Inclusion criteria focused on studies related to natural products, bioactive compounds, medicinal plants, phytochemistry, and AI applications in drug discovery. Data were categorized into source, extraction methods, bioactivity assays, and technological advances. The current review underscores the historical and ongoing importance of natural products in drug discovery. Technological advancements in chromatographic and spectroscopic techniques have improved the isolation and structural elucidation of bioactive compounds. AI and machine learning have streamlined the identification and optimization of natural product leads. Challenges such as biodiversity sustainability and development complexities are discussed, alongside innovative approaches like biosynthetic engineering and metagenomics. Natural products remain a vital source of novel therapeutic agents, providing unique chemical diversity and specific biological activities. Integrating traditional knowledge with modern scientific methods is essential for maximizing the potential of natural products in drug discovery. Despite existing challenges, ongoing research and technological advancements are expected to enhance the efficiency and success of natural product-based drug development.
- 2 December 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (5) , 4673-4687
Top Cited PapersNatural products as drug leads: exploring their potential in drug discovery and development
Natural products have been pivotal in drug discovery, offering a wealth of bioactive compounds that significantly contribute to therapeutic developments. Despite the rise of synthetic chemistry, natural products continue to play a crucial role due to their unique chemical structures and diverse biological activities. This study reviews and evaluates the potential of natural products in drug discovery and development, emphasizing the integration of traditional knowledge with modern drug discovery methodologies and addressing the associated challenges. A comprehensive literature search was conducted across PubMed/MedLine, Scopus, Web of Science, Google Scholar, and Cochrane Library, covering publications from 2000 to 2023. Inclusion criteria focused on studies related to natural products, bioactive compounds, medicinal plants, phytochemistry, and AI applications in drug discovery. Data were categorized into source, extraction methods, bioactivity assays, and technological advances. The current review underscores the historical and ongoing importance of natural products in drug discovery. Technological advancements in chromatographic and spectroscopic techniques have improved the isolation and structural elucidation of bioactive compounds. AI and machine learning have streamlined the identification and optimization of natural product leads. Challenges such as biodiversity sustainability and development complexities are discussed, alongside innovative approaches like biosynthetic engineering and metagenomics. Natural products remain a vital source of novel therapeutic agents, providing unique chemical diversity and specific biological activities. Integrating traditional knowledge with modern scientific methods is essential for maximizing the potential of natural products in drug discovery. Despite existing challenges, ongoing research and technological advancements are expected to enhance the efficiency and success of natural product-based drug development.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 25 (16) , 2060-2077
Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics
: Pharmaceutical design has made significant advancements in recent years, leading to the development of novel therapeutics with unprecedented efficacy and safety profiles. This review highlights the potential of these innovations to revolutionize healthcare and improve patient outcomes. The application of cutting-edge technologies like artificial intelligence, machine learning, and data mining in drug discovery and design has made it easier to find potential drug candidates. Combining big data and omics has led to the discovery of new therapeutic targets and personalized medicine strategies. Nanoparticles, liposomes, and microneedles are examples of advanced drug delivery systems that allow precise control over drug release, better bioavailability, and targeted delivery to specific tissues or cells. This improves the effectiveness of the treatment while reducing side effects. Stimuli-responsive materials and smart drug delivery systems enable drugs to be released on demand when specific internal or external signals are sent. Biologics and gene therapies are promising approaches in pharmaceutical design, offering high specificity and potency for treating various diseases like cancer, autoimmune disorders, and infectious diseases. Gene therapies hold tremendous potential for correcting genetic abnormalities, with recent breakthroughs demonstrating successful outcomes in inherited disorders and certain types of cancer. Advancements in nanotechnology and nanomedicine have paved the way for innovative diagnostic tools and therapeutics, such as nanoparticle-based imaging agents, targeted drug delivery systems, gene editing technologies, and regenerative medicine strategies. Finally, the review emphasizes the importance of regulatory considerations, ethical challenges, and future directions in pharmaceutical design. Regulatory agencies are adapting to the rapid advancements in the field, ensuring the safety and efficacy of novel therapeutics while fostering innovation. Ethical considerations regarding the use of emerging technologies, patient privacy, and access to advanced therapies also require careful attention.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 25 (16) , 2060-2077
Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics
: Pharmaceutical design has made significant advancements in recent years, leading to the development of novel therapeutics with unprecedented efficacy and safety profiles. This review highlights the potential of these innovations to revolutionize healthcare and improve patient outcomes. The application of cutting-edge technologies like artificial intelligence, machine learning, and data mining in drug discovery and design has made it easier to find potential drug candidates. Combining big data and omics has led to the discovery of new therapeutic targets and personalized medicine strategies. Nanoparticles, liposomes, and microneedles are examples of advanced drug delivery systems that allow precise control over drug release, better bioavailability, and targeted delivery to specific tissues or cells. This improves the effectiveness of the treatment while reducing side effects. Stimuli-responsive materials and smart drug delivery systems enable drugs to be released on demand when specific internal or external signals are sent. Biologics and gene therapies are promising approaches in pharmaceutical design, offering high specificity and potency for treating various diseases like cancer, autoimmune disorders, and infectious diseases. Gene therapies hold tremendous potential for correcting genetic abnormalities, with recent breakthroughs demonstrating successful outcomes in inherited disorders and certain types of cancer. Advancements in nanotechnology and nanomedicine have paved the way for innovative diagnostic tools and therapeutics, such as nanoparticle-based imaging agents, targeted drug delivery systems, gene editing technologies, and regenerative medicine strategies. Finally, the review emphasizes the importance of regulatory considerations, ethical challenges, and future directions in pharmaceutical design. Regulatory agencies are adapting to the rapid advancements in the field, ensuring the safety and efficacy of novel therapeutics while fostering innovation. Ethical considerations regarding the use of emerging technologies, patient privacy, and access to advanced therapies also require careful attention.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Enzyme Inhibition
- Vol. 20 (1) , 2-19
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Enzyme inhibition is a crucial mechanism for regulating biological processes and developing therapeutic interventions. This pharmacological review summarizes recent advances in enzyme inhibition, focusing on key developments and their implications for drug discovery and therapeutic strategies. It explains basic ideas, including the different kinds of inhibitors and how they work, and looks at recent advances in small-molecule inhibitor design, fragment-based drug discovery, and virtual screening techniques. The review also highlights the advances in targeting specific enzyme families, explaining the structural basis of enzyme-inhibitor interactions, optimizing inhibitor potency, selectivity, and pharmacokinetic properties, and new trends in enzyme inhibition. The clinical implications of recent advances in enzyme inhibition include the development of novel therapeutic agents for diseases like cancer, infectious diseases, and neurological disorders. The review addresses challenges and future directions in the field, such as optimizing drug safety, resistance mechanisms, and personalized medicine approaches. Overall, the insights provided in this review may inspire further research and collaborations to accelerate the translation of enzyme inhibitors into effective clinical treatments.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Enzyme Inhibition
- Vol. 20 (1) , 2-19
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Enzyme inhibition is a crucial mechanism for regulating biological processes and developing therapeutic interventions. This pharmacological review summarizes recent advances in enzyme inhibition, focusing on key developments and their implications for drug discovery and therapeutic strategies. It explains basic ideas, including the different kinds of inhibitors and how they work, and looks at recent advances in small-molecule inhibitor design, fragment-based drug discovery, and virtual screening techniques. The review also highlights the advances in targeting specific enzyme families, explaining the structural basis of enzyme-inhibitor interactions, optimizing inhibitor potency, selectivity, and pharmacokinetic properties, and new trends in enzyme inhibition. The clinical implications of recent advances in enzyme inhibition include the development of novel therapeutic agents for diseases like cancer, infectious diseases, and neurological disorders. The review addresses challenges and future directions in the field, such as optimizing drug safety, resistance mechanisms, and personalized medicine approaches. Overall, the insights provided in this review may inspire further research and collaborations to accelerate the translation of enzyme inhibitors into effective clinical treatments.